
NASDAQHealthcareMedical - Devices
أحدث البيانات المتاحة
2.33 US$
+0.03 US$ · +1.30%
Pacific Biosciences of California, Inc. (PACB) specializes in pioneering and manufacturing advanced genetic sequencing platforms, empowering researchers and institutions to unravel intricate genetic challenges. At the heart of its offerings are the proprietary PacBio Sequencing Systems, designed for executing, monitoring, and interpreting biochemical sequencing reactions. Complementing these instruments are essential consumable products, such as their unique single molecule real-time (SMRT) cells. Furthermore, the company supplies a comprehensive suite of workflow-specific reagent kits. These include template preparation kits, which utilize molecular biology reagents (like ligase, buffers, and exonucleases) to convert DNA into SMRTbell double-stranded DNA libraries. Binding kits, featuring modified DNA polymerase, facilitate the crucial attachment of SMRTbell libraries to the polymerase in readiness for sequencing. Finally, specialized sequencing kits contain all necessary reagents, including phospholinked nucleotides, for real-time sequencing directly on their instruments. Pacific Biosciences caters to a broad global clientele, encompassing prominent research institutions, commercial diagnostic laboratories, large-scale genome centers, public health organizations, hospitals, clinical research institutes, contract research organizations (CROs), academic bodies, pharmaceutical firms, and agricultural enterprises. Product commercialization is managed through a direct sales force across North America and Europe, complemented by a robust network of distribution partners spanning Asia, the Middle East, Africa, and Latin America. A significant strategic alliance includes a development and commercialization agreement with Invitae Corporation. Originally incorporated in 2000 as Nanofluidics, Inc., the company adopted its current name, Pacific Biosciences of California, Inc., in 2005. Its corporate headquarters are situated in Menlo Park, California.
الإغلاق السابق
2.33 US$
+0.03 US$ · +1.30%
بعد ساعات التداول
2.32 US$
−0.01 US$ · -0.43%
9 أكتوبر، 7:30 م ET
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
Pacific Biosciences of California, Inc. (PACB) specializes in pioneering and manufacturing advanced genetic sequencing platforms, empowering researchers and institutions to unravel intricate genetic challenges. At the heart of its offerings are the proprietary PacBio Sequencing Systems, designed for executing, monitoring, and interpreting biochemical sequencing reactions. Complementing these instruments are essential consumable products, such as their unique single molecule real-time (SMRT) cells. Furthermore, the company supplies a comprehensive suite of workflow-specific reagent kits. These include template preparation kits, which utilize molecular biology reagents (like ligase, buffers, and exonucleases) to convert DNA into SMRTbell double-stranded DNA libraries. Binding kits, featuring modified DNA polymerase, facilitate the crucial attachment of SMRTbell libraries to the polymerase in readiness for sequencing. Finally, specialized sequencing kits contain all necessary reagents, including phospholinked nucleotides, for real-time sequencing directly on their instruments. Pacific Biosciences caters to a broad global clientele, encompassing prominent research institutions, commercial diagnostic laboratories, large-scale genome centers, public health organizations, hospitals, clinical research institutes, contract research organizations (CROs), academic bodies, pharmaceutical firms, and agricultural enterprises. Product commercialization is managed through a direct sales force across North America and Europe, complemented by a robust network of distribution partners spanning Asia, the Middle East, Africa, and Latin America. A significant strategic alliance includes a development and commercialization agreement with Invitae Corporation. Originally incorporated in 2000 as Nanofluidics, Inc., the company adopted its current name, Pacific Biosciences of California, Inc., in 2005. Its corporate headquarters are situated in Menlo Park, California.
نطاق اليوم
السعر الحالي 2.33 US$
نطاق 52 أسبوعًا
السعر الحالي 2.33 US$
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
نقاط GoAI
بيع
تقييم
57
قيمة عادلة
المشاعر
43
مختلط
المخاطر
77
مخاطر مرتفعة
الزخم
48
محايد
بحث كامل عن GoAI
تابع للاطلاع على أدلة ومحفزات ومخاطر أعمق.
Pacific Biosciences of California, Inc. (PACB) specializes in pioneering and manufacturing advanced genetic sequencing platforms, empowering researchers and institutions to unravel intricate genetic challenges. At the heart of its offerings are the proprietary PacBio Sequencing Systems, designed for executing, monitoring, and interpreting biochemical sequencing reactions. Complementing these instruments are essential consumable products, such as their unique single molecule real-time (SMRT) cells. Furthermore, the company supplies a comprehensive suite of workflow-specific reagent kits. These include template preparation kits, which utilize molecular biology reagents (like ligase, buffers, and exonucleases) to convert DNA into SMRTbell double-stranded DNA libraries. Binding kits, featuring modified DNA polymerase, facilitate the crucial attachment of SMRTbell libraries to the polymerase in readiness for sequencing. Finally, specialized sequencing kits contain all necessary reagents, including phospholinked nucleotides, for real-time sequencing directly on their instruments. Pacific Biosciences caters to a broad global clientele, encompassing prominent research institutions, commercial diagnostic laboratories, large-scale genome centers, public health organizations, hospitals, clinical research institutes, contract research organizations (CROs), academic bodies, pharmaceutical firms, and agricultural enterprises. Product commercialization is managed through a direct sales force across North America and Europe, complemented by a robust network of distribution partners spanning Asia, the Middle East, Africa, and Latin America. A significant strategic alliance includes a development and commercialization agreement with Invitae Corporation. Originally incorporated in 2000 as Nanofluidics, Inc., the company adopted its current name, Pacific Biosciences of California, Inc., in 2005. Its corporate headquarters are situated in Menlo Park, California.
نطاق اليوم
السعر الحالي 2.33 US$
نطاق 52 أسبوعًا
السعر الحالي 2.33 US$
الربحية كنسبة مئوية من الإيرادات المعلنة.
الإيرادات
الدخل التشغيلي
صافي الدخل
| البند (USD) | السنة المالية 2025 | السنة المالية 2024 | السنة المالية 2023 | السنة المالية 2022 | السنة المالية 2021 |
|---|---|---|---|---|---|
| الإيرادات | 160.01 مليون USD | 154.01 مليون USD | 200.52 مليون USD | 128.3 مليون USD | 130.51 مليون USD |
| تكلفة البضاعة المباعة | 109.33 مليون USD | 116.73 مليون USD | 147.74 مليون USD | 79.27 مليون USD | 71.65 مليون USD |
| الربح الإجمالي | 50.67 مليون USD | 37.28 مليون USD | 52.78 مليون USD | 49.04 مليون USD | 58.86 مليون USD |
| البحث والتطوير | 97.31 مليون USD | 134.92 مليون USD | 187.17 مليون USD | 193 مليون USD | 112.9 مليون USD |
| مصاريف البيع والمصاريف العمومية والإدارية | 141.49 مليون USD | 175.02 مليون USD | 169.82 مليون USD | 160.85 مليون USD | 124.12 مليون USD |
| نفقات التشغيل | 608.24 مليون USD | 511.6 مليون USD | 387.25 مليون USD | 356.23 مليون USD | 269.3 مليون USD |
| مصاريف الفوائد | 6.95 مليون USD | 13.41 مليون USD | 14.34 مليون USD | 14.69 مليون USD | 12.53 مليون USD |
| الاستهلاك والإطفاء | 386.41 مليون USD | 53.35 مليون USD | 32.69 مليون USD | 17.32 مليون USD | 11.59 مليون USD |
| الدخل التشغيلي | −557.56 مليون USD | −474.31 مليون USD | −334.47 مليون USD | −307.2 مليون USD | −210.44 مليون USD |
| صافي الدخل | −546.38 مليون USD | −309.85 مليون USD | −306.74 مليون USD | −314.25 مليون USD | −181.22 مليون USD |
تم تحديث حقائق الشركة 10 أكتوبر 2026.
أحدث النتائج المعلنة
أحدث النتائج المعلنة
قد تتغير تقديرات المحللين الخارجيين، وهي ليست توصيات من GoAI.
متوسط الهدف
1.18 US$
انخفاض محتمل بنسبة 49.36%صناديق متداولة تفصح عن تعرضها لهذا السهم.
ARK Innovation ETFARKK29.16 مليون0.42%5.56 مليار USD0.75%89.62 US$+2.31%
ARK Genomic Revolution ETFARKG25.15 مليون1.23%1.56 مليار USD0.75%51.30 US$+4.08%
iShares Russell 2000 ETFIWM17.28 مليون0.02%78.27 مليار USD0.19%278.94 US$+0.49%
Vanguard Morningstar Total Stock Market ETFVTI12.92 مليون0.00%2.3 ترليون USD0.03%381.94 US$+0.63%
iShares Russell 2000 Growth ETFIWO5.67 مليون0.04%13.97 مليار USD0.24%356.78 US$+0.94%
iShares Biotechnology ETFIBB5.19 مليون0.05%10.28 مليار USD0.44%206.49 US$+3.00%
Vanguard Extended Market ETFVXF4.92 مليون0.01%95.4 مليار USD0.05%235 US$+0.80%
Schwab U.S. Small-Cap ETFSCHA3.75 مليون0.02%21.73 مليار USD0.03%32.79 US$+0.40%
ARK Innovation ETFARKK
ARK Genomic Revolution ETFARKG
iShares Russell 2000 ETFIWM
Vanguard Morningstar Total Stock Market ETFVTI
iShares Russell 2000 Growth ETFIWO
iShares Biotechnology ETFIBB
Vanguard Extended Market ETFVXF
Schwab U.S. Small-Cap ETFSCHAالمحتوى المُنشأ بالذكاء الاصطناعي وبيانات السوق المتأخرة لأغراض معلوماتية وتعليمية فقط، ولا تُعد نصيحة استثمارية.